The Ministry of Health and Prevention, MoHAP, in partnership with Abbott, has revealed the success of implanting the highly precise device “CardioMEMS PA sensor” for patients with heart failure. The announcement comes as part of MoHAP’s participation in the Arab Health 2020, Dubai, which lasts until January 30.

The new device reduces hospital admissions by 58%, as it can predict the health condition of the patient's heart and send an email to his doctor if there are indications of heart failure, thus taking the necessary treatment measures.

The CardioMEMS ™ HF system features a wireless sensor that is implanted in the pulmonary artery (PA) to directly measure PA pressure of patients with advanced heart failure.

The CardioMEMS HF System allows patients to transmit critical information about their heart failure status to a clinician on a regular basis, without the need for additional clinic or hospital visits. This provides clinicians with the ability to detect worsening heart failure sooner and adjust treatment to reduce the likelihood that the patient will need to be hospitalized.

Predictive Treatment Solutions

The device is measuring the percentage of fluid trapped in the pulmonary artery causing heart failure and it doesn’t require batteries or replaceable parts. Once implanted, it measures the PA pressure precisely and continuously.

This helps detect symptoms in earlier stages and contributes to faster treatment, in addition to reducing the rate of hospitalization and the death rate due to heart failure.